Pembrolizumab Plus Chemo Provides Overall Survival Benefit in Endometrial Cancer
Dostarlimab Plus Chemo Demonstrates 31% OS Improvement in Advanced Endometrial Cancer
Olaparib Plus Cediranib May Not Provide Survival Benefit in Platinum-Resistant or Refractory Ovarian Cancer
Mirvetuximab Soravtansine Bests Chemo in HRQOL for FRα+ Ovarian Cancer
2 Commerce Drive
Cranbury, NJ 08512